Explore how adjuvant osimertinib aids in detecting molecular residual disease in resected EGFR-mutated NSCLC, offering ...

Following the interim assessment using the test ... The trial will also explore end of therapy ctDNA-MRD analysis as an exploratory endpoint. According to the company, the standard treatment for newly ...

Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in ...

Early clearance of measurable residual disease (MRD) after induction therapy in patients with acute myeloid leukemia (AML) is associated with significantly better relapse-free survival (RFS ...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...

COG made residual disease assessment a standard prognostic indicator in clinical trials of treatments for pediatric acute lymphoblastic leukemia (ALL). While the overall relapse rate for pediatric ...

which included language recommending ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of first-line treatment.

which included language recommending ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of first-line treatment. DLBCL is the most common form of non-Hodgkin lymphoma ...